ATE353976T1 - Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen - Google Patents

Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen

Info

Publication number
ATE353976T1
ATE353976T1 AT02756005T AT02756005T ATE353976T1 AT E353976 T1 ATE353976 T1 AT E353976T1 AT 02756005 T AT02756005 T AT 02756005T AT 02756005 T AT02756005 T AT 02756005T AT E353976 T1 ATE353976 T1 AT E353976T1
Authority
AT
Austria
Prior art keywords
methods
lung
compositions
assessing
function
Prior art date
Application number
AT02756005T
Other languages
English (en)
Inventor
Robert Peter Young
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of ATE353976T1 publication Critical patent/ATE353976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02756005T 2001-06-05 2002-06-05 Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen ATE353976T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ51216901 2001-06-05
NZ51301601 2001-07-17
NZ51427501 2001-09-18

Publications (1)

Publication Number Publication Date
ATE353976T1 true ATE353976T1 (de) 2007-03-15

Family

ID=27353936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756005T ATE353976T1 (de) 2001-06-05 2002-06-05 Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen

Country Status (15)

Country Link
US (2) US20040219548A1 (de)
EP (2) EP1801240A1 (de)
JP (1) JP2004532640A (de)
AT (1) ATE353976T1 (de)
AU (1) AU2002323841B2 (de)
CA (1) CA2449647A1 (de)
CY (1) CY1107625T1 (de)
DE (1) DE60218162T2 (de)
DK (1) DK1402073T3 (de)
ES (1) ES2282444T3 (de)
HK (1) HK1065336A1 (de)
NZ (1) NZ545283A (de)
PT (1) PT1402073E (de)
SG (1) SG143977A1 (de)
WO (1) WO2002099134A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
WO2005092383A1 (ja) * 2004-03-26 2005-10-06 Takeda Pharmaceutical Company Limited 呼吸器疾患の予防・治療剤
GB0508023D0 (en) * 2005-04-21 2005-05-25 Univ Nottingham Pulmonary disease marker
JP2006314315A (ja) * 2005-05-10 2006-11-24 Synergenz Bioscience Ltd 肺の機能と異常を調べるための方法と組成物
EP1896607A4 (de) * 2005-05-10 2009-12-16 Synergenz Bioscience Ltd Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen
US8076065B2 (en) 2005-05-19 2011-12-13 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
EP1888776A4 (de) * 2005-05-19 2009-07-29 Synergenz Bioscience Ltd Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen
WO2006123943A1 (en) 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
EP2074224A4 (de) * 2006-10-17 2010-07-21 Synergenz Bioscience Ltd Verfahren und zusammensetzungen zur beurteilung von lungenfunktion und lungenleiden
US20110184044A1 (en) * 2008-05-12 2011-07-28 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
PL3257953T3 (pl) 2009-03-12 2019-05-31 Cancer Prevention & Cure Ltd Sposoby identyfikacji, oceny, zapobiegania i terapii chorób płuc, ich zestawy, w tym do identyfikacji, oceny, zapobiegania i terapii chorób powiązanych z płcią
CN111826383B (zh) * 2020-07-16 2022-08-02 昆明理工大学 丹波黑大豆超氧化物歧化酶基因在提高植物铝耐受性中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829052A (en) * 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5827662A (en) * 1989-06-23 1998-10-27 The Trustees Of The University Of Pennsylvania Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
US5844108A (en) * 1990-06-22 1998-12-01 Roche Molecular Systems, Inc. Primers targeted to NAT2 gene for detection of poor metabolizers of drugs
EP1262493A1 (de) * 1992-10-29 2002-12-04 Bayer Corporation Diagnostischer Test spezifisch für die latente Matrix Metalloproteinase no. 9
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
JPH07303482A (ja) * 1993-11-30 1995-11-21 Fuji Yakuhin Kogyo Kk 新規なメタロプロテアーゼおよびそれをコードするｄｎａ
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US6022893A (en) * 1995-08-08 2000-02-08 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives
EP0785216B2 (de) * 1995-12-18 2006-06-07 The University of Utah Research Foundation Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
US5837492A (en) * 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US5932579A (en) * 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
US6060283A (en) * 1996-06-27 2000-05-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US20060122373A1 (en) * 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
EP0975752A1 (de) * 1997-04-29 2000-02-02 Regeneron Pharmaceuticals, Inc. Menschliches cerberusprotein
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
US5935852A (en) * 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
US6211209B1 (en) * 1997-08-08 2001-04-03 Warner-Lambert Company Method of inhibiting connective tissue degradation
AU747991B2 (en) * 1997-12-16 2002-05-30 Teijin Limited Analysis of predisposition based on human airway tripsin protease gene polymorphism
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6117869A (en) * 1998-08-04 2000-09-12 Warner-Lambert Company Compounds for and methods of inhibiting matrix metalloproteinases
US6183963B1 (en) * 1998-10-23 2001-02-06 Signalgene Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay
US6677442B1 (en) * 1999-10-29 2004-01-13 University Of Kentucky Research Foundation Nucleic acid encoding human REV1 protein
US6187587B1 (en) * 2000-03-02 2001-02-13 Isis Pharmaceuticals, Inc. Antisense inhibition of e2f transcription factor 1 expression
US6716581B2 (en) * 2000-03-31 2004-04-06 University Of Southern California Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050064454A1 (en) * 2000-06-05 2005-03-24 Young Paul E. Cancer gene determination and therapeutic screening using signature gene sets
US20040209254A1 (en) 2000-07-25 2004-10-21 Henderson Lee A. Diagnostic polymorphisms for the tgf-beta1 promoter
US6673549B1 (en) * 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
TW200504223A (en) * 2003-02-04 2005-02-01 Innovaceuticals Inc Methods of assessment of drug metabolizing enzymes
US20050272054A1 (en) * 2003-11-26 2005-12-08 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof

Also Published As

Publication number Publication date
DE60218162D1 (de) 2007-03-29
WO2002099134B1 (en) 2003-02-13
EP1402073A4 (de) 2005-11-02
CA2449647A1 (en) 2002-12-12
WO2002099134A1 (en) 2002-12-12
JP2004532640A (ja) 2004-10-28
DK1402073T3 (da) 2007-06-11
EP1402073B1 (de) 2007-02-14
US20120142000A1 (en) 2012-06-07
EP1801240A1 (de) 2007-06-27
EP1402073A1 (de) 2004-03-31
SG143977A1 (en) 2008-07-29
DE60218162T2 (de) 2007-10-31
NZ545283A (en) 2008-01-31
ES2282444T3 (es) 2007-10-16
US20040219548A1 (en) 2004-11-04
HK1065336A1 (en) 2005-02-18
AU2002323841B2 (en) 2008-05-22
CY1107625T1 (el) 2013-03-13
PT1402073E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
CY1107625T1 (el) Μεθοδοι και συνθεσεις για αποτιμηση πνευμονικης λειτουργιας και διαταραχων
Bradford et al. The value of blood cytokines and chemokines in assessing COPD
WO2008048120A3 (en) Methods and compositions for assessment of pulmonary function and disorders
Jongepier et al. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma
Repapi et al. Genome-wide association study identifies five loci associated with lung function
Navratilova et al. Simultaneous up‐regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease
WO2007120480A3 (en) Systems and methods for predicting effectiveness in the treatment of psychiatric disorders, including depression
NO20075193L (no) Fremgangsmater for behandling og forebygging av IL-21/IL-21R antagonister
ATE523601T1 (de) Verfahren und zusammensetzungen zur vorhersage der reaktion auf warfarin
WO2007050794A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
Wang et al. Association of ADAM33 gene polymorphisms with COPD in a northeastern Chinese population
WO2006123955A3 (en) Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
Shoji et al. Clinical usefulness of simultaneous measurement of the tear levels of CCL17, CCL24, and IL-16 for the biomarkers of allergic conjunctival disorders
Hedbrant et al. Quartz Dust Exposure Affects NLRP3 Inflammasome Activation and Plasma Levels of IL‐18 and IL‐1Ra in Iron Foundry Workers
WO2006121351A3 (en) Methods and compositions for assessment of pulmonary function and disorders
Abd El-Fatah et al. Identification of MMP-9 as a biomarker for detecting progression of chronic obstructive pulmonary disease
Gilowska et al. The role of MMP-12 gene polymorphism− 82 A-to-G (rs2276109) in immunopathology of COPD in polish patients: a case control study
Wang et al. Genetic variants in ADAM33 are associated with airway inflammation and lung function in COPD
Sumner et al. Epigenetics of early-life adversity in youth: cross-sectional and longitudinal associations
WO2008075977A3 (en) Methods and compositions for the assessment of cardiovascular function and disorders
Sauler et al. Single-cell RNA sequencing identifies aberrant transcriptional profiles of cellular populations and altered alveolar niche signalling networks in Chronic Obstructive Pulmonary Disease (COPD)
EP2443258A4 (de) Verfahren und zusammensetzungen zur beurteilung von lungenfunktion und lungenleiden
Shoeb et al. Silica inhalation altered telomere length and gene expression of telomere regulatory proteins in lung tissue of rats
Grunig et al. Challenges and current efforts in the development of biomarkers for chronic inflammatory and remodeling conditions of the lungs
WO2003064600A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1402073

Country of ref document: EP

REN Ceased due to non-payment of the annual fee